4564 — OncoTherapy Science Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapSucker Stock

Annual income statement for OncoTherapy Science, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	281	316	332	1,154	1,135
Cost of Revenue
Gross Profit	—	-50.1	19.5	114	41.7
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,470	2,596	1,891	3,705	2,225
Operating Profit	-3,189	-2,280	-1,559	-2,551	-1,090
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-3,195	-2,237	-1,560	-2,570	-1,116
Provision for Income Taxes
Net Income After Taxes	-3,192	-2,239	-1,562	-2,572	-1,119
Minority Interest
Net Income Before Extraordinary Items
Net Income	-2,935	-2,239	-1,562	-2,572	-1,119
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-2,935	-2,239	-1,562	-2,572	-1,119
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-18.9	-13.6	-9.15	-12	-5.86
Dividends per Share